PharmaShots

MAY 3, 2023

Shots: The NICE has recommended Lupkynis in combination with mycophenolate mofetil for use within NHS England & NHS Wales in adults with active LN class III, IV, or V The recommendation was based on the P-III study (AURORA 1 & 2) evaluating voclosporin + MMF & corticosteroids vs MMF & corticosteroids alone.

40

40

pharmaphorum

JANUARY 14, 2021

Previous COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit the virus, according to a study by Public Health England. As a result, PHE stressed the importance of following “stay at home” rules currently in place in the UK to prevent the virus from spreading.

Immunization 65

Immunization Vaccines 65

pharmaphorum

JANUARY 28, 2021

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE. Across the UK, around 1,500 newly diagnosed myeloma patients undergo a transplant each year, and most of them eventually relapse.

98

98

pharmaphorum

OCTOBER 12, 2020

It was supposed to be at the heart of the UK government’s fight against coronavirus – but after months of delays it has emerged that the NHS COVID-19 app has sent just one alert over a potentially infected venue. Coronavirus cases are spiralling out of control across the UK, with numbers of cases not seen since the national lockdown in March.

58

58

pharmaphorum

OCTOBER 6, 2020

An Excel spreadsheet was behind IT glitch that caused thousands of positive COVID-19 tests to be omitted from the UK’s official records, according to press reports. The post Excel spreadsheet blamed for UK’s COVID-19 test and trace woes appeared first on.

Hospitals 127

Hospitals Vaccines 127

pharmaphorum

DECEMBER 13, 2021

The UK government has said it will step up its COVID-19 booster vaccination dramatically, with everyone in England aged over 18 offered a third dose before the end of the month. So far, there have been 10 confirmed hospitalisations in the UK involving Omicron, but no deaths attributed to the new variant, said Javid.

Vaccines 52

Vaccines 52

pharmaphorum

OCTOBER 14, 2020

A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England. The post Scotland backs two myeloma drugs turned down by NICE in England appeared first on. Image by Neil Cumins from Pixabay.

52

52

pharmaphorum

JANUARY 19, 2021

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England. NICE has previously estimated that roughly 412 patients across the UK are have NSCLC eligible for treatment with Rozlytrek. Other decisions.

Chemotherapy 89

Chemotherapy Immunization 89

pharmaphorum

FEBRUARY 16, 2021

UK health chiefs have urged caution over any relaxation of lockdown rules amid signs that the impact of vaccination and social distancing regulations are beginning to work. Around 300 volunteers will take part in the UK trial, with the first vaccinations taking place later in February.

Vaccines 58

Vaccines Hospitals Immunization 58

pharmaphorum

JANUARY 9, 2023

The transaction will be effected by means of a UK scheme of arrangement under Part 26 of the UK Companies Act 2006, subject to approval of Amryt shareholders, sanction by the High Court of Justice of England and Wales, and other customary closings, including regulatory/antitrust approvals.

FDA 90

FDA 90

Pharmaceutical Technology

MARCH 31, 2023

This, paired with the recent news that the US Senate voted to end the Covid-19 National Emergency Declaration early, suggests that innovative vaccines are flying off the development lines only to enter the market when legislature and funding to support vaccine rollout is becoming less certain.

Vaccines 110

Vaccines Immunization 110

Pharmaceutical Technology

SEPTEMBER 26, 2022

The UK National Institute for Health and Care Excellence (NICE) has granted approval for Pfizer ’s palbociclib (Ibrance) in combination with anti-cancer therapy, fulvestrant, to treat advanced breast cancer patients. The post UK NICE grants approval for breast cancer drug combination appeared first on Pharmaceutical Technology.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

FEBRUARY 24, 2022

According to GSK, the transition from interim CDF funding to routine commissioning in second line therapy offers long-term certainty of access for eligible patients in England. At least 41,000 women in the UK are estimated to be living with ovarian cancer. The post GSK’s ZEJULA gets green light for NHS use appeared first on.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

AUGUST 17, 2022

The indicators did not bring universal good news , but Leela Barham argues we need to consider whether the indicators are measuring what matters most if we are to understand more about the health of the UK life sciences industry and, most importantly, what it means for patients. Interest in indicators. The life sciences ecosystem.

58

58

pharmaphorum

APRIL 13, 2021

A disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland gave a green light to use of PTC Therapeutics’ Translarna for the first time. . — Duchenne UK (@DuchenneUK) April 12, 2021. Dupixent recommended after NICE rejection.

52

52

pharmaphorum

OCTOBER 19, 2022

Patients across the UK with chronic immune thrombocytopenia (ITP) now have another treatment option, after NICE backed use of Spanish drugmaker Grifols’ Tavlesse for adults with the rare blood disorder. Fostamatinib will be another tool for haematologists to use in supporting patients with chronic ITP.”

Immunization 52

Immunization Documentation 52

pharmaphorum

DECEMBER 22, 2020

BioNTech CEO Ugur Sahin has said that it is “highly likely” the company’s COVID-19 vaccine will work against the more infectious strain circulating in the south east of England, although further studies will be needed. Sahin said: “We don’t know at the moment if our vaccine is also able to provide protection against this new variant.

Vaccines 76

Vaccines Immunization 76

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig was cleared for use by NHS Scotland last year, with Ajovy given a green light in January 2020.

80

80

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig was cleared for use by NHS Scotland last year, with Ajovy given a green light in January 2020.

76

76

pharmaphorum

SEPTEMBER 28, 2020

NHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it the first and only medicine backed for what is the most common inherited bleeding disorder in the UK. Access to Veyvondi will be primarily via Haemophilia Comprehensive Care Centres (CCC), according to the CPAG.

Documentation 68

Documentation 68

Hospital Pharmacy Europe

NOVEMBER 9, 2023

NICE and NHS England have agreed that this wearable technology will be rolled out over a five-year period in order to allow for trusts to employ the extra staff needed and for specialist training for both patients and staff to be completed.

Hospitals 52

Hospitals 52

pharmaphorum

NOVEMBER 13, 2020

US data analysis company Palantir Technologies could be drafted in to manage the UK government’s troubled COVID-19 Test and Trace programme, according to press reports. Before the government called a month-long national lockdown, it struggled to keep on top of rising numbers of cases in the north of England with its targeted local approach.

Documentation 93

Documentation 93

Pharmaceutical Technology

JANUARY 27, 2023

The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Kite’s axicabtagene ciloleucel (yescarta) to treat aggressive forms of lymphoma. Between December 2018 and October 2021 in England, 318 people received axicabtagene ciloleucel through the CDF.

Communication 59

Communication Immunization 59

pharmaphorum

NOVEMBER 11, 2021

The publication of a new report from healthcare analytics firm LOGEX, with the Institute for Rational Use of Medicine (IVM), on uptake in England should provide plenty of food for thought for the pharmaceutical industry. The good news? The bad news? Read the LOGEX report on medicines uptake in England.

Dosage 52

Dosage 52

European Pharmaceutical Review

NOVEMBER 30, 2023

Looking ahead to the next twelve months, several significant manufacturing projects in the UK are planning to become GMP operational. Currently, there are 28 facilities which are licensed for advanced therapy manufacturing in the UK, Ward elaborated. So now we have a really nice blend.”

Medical Schools 77

Medical Schools 77

pharmaphorum

DECEMBER 8, 2022

A post from the director of health and life sciences at Innovate UK, Richard J Hebdon, also bigged up the news before the Council met about four health missions. 6. Amanda Pritchard (Chief Executive, NHS England). 9. Professor Dame Ottoline Leyser (CEO, UK Research and Innovation). That was just in November alone.

Documentation 97

Documentation 97

Hospital Pharmacy Europe

NOVEMBER 6, 2023

Helen Knight, director of medicines evaluation at NICE, said: ’Foslevodopa-foscarbidopa represents an important new treatment for people with advanced Parkinson’s, providing an easy-to-use option that can help them manage their symptoms more reliably and effectively.

Hospitals 52

Hospitals 52

pharmaphorum

MARCH 31, 2022

More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose monitoring (CGM) technology, reducing their reliance on fingerprick testing, according to NICE. At the moment, flash CGM has been rolled out to around half of patients with type 1 diabetes by NHS England. Exciting news!

52

52

pharmaphorum

APRIL 12, 2021

The new version of the app used in England and Wales was due to become available today to coincide with the relaxation of lockdown rules, with the public now able to attend venues such as non-essential shops, pub beer garden, gyms and hairdressers.

138

138

pharmaphorum

SEPTEMBER 23, 2022

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer’s targeted therapy Ibrance, thanks to new guidance from NICE. “After a median follow-up of 73.3 months in the trial, median overall survival was 6.8

Documentation 52

Documentation 52

pharmaphorum

JANUARY 26, 2021

More than 100,000 people have died within 28 days of a positive COVID-19 test in the UK, the first European country to meet that grim milestone. The UK is only the fifth country after the US, Brazil, India and Mexico to pass that threshold, after a surge in cases following the holiday period around the turn of the year. He also said 6.8

Vaccines 58

Vaccines 58

pharmaphorum

FEBRUARY 3, 2021

NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – but a patient group warned that access could be limited until the pandemic recedes because of disruption to ophthalmology clinics.

Labelling 98

Labelling Hospitals 98

pharmaphorum

OCTOBER 11, 2022

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD’s Keytruda in combination with Eisai’s Lenvima as a treatment for advanced or recurrent endometrial cancer. The post Scotland backs three new uses for MSD’s Keytruda appeared first on.

Chemotherapy 52

Chemotherapy Documentation 52

pharmaphorum

JUNE 7, 2021

A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Poteligeo for two rare blood cancers, a few weeks after the drug was turned in England by NICE. There is currently no licensed treatment option for this condition, said the SMC.

52

52

pharmaphorum

MARCH 9, 2022

There isn’t enough evidence to support the use of Merck & Co/MSD’s Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the UK cost effectiveness watchdog NICE. Its long-term benefits are uncertain. .”

Chemotherapy 74

Chemotherapy 74

pharmaphorum

DECEMBER 7, 2022

Free to those over 50, the NHS Health Check is available to approximately 15 million people in England, according to the Department of Health and Social Care (DHSC). Those who have results suggesting an underlying health condition will be followed up with within the GP practice setting.

58

58

pharmaphorum

JANUARY 20, 2023

billion prescribing records harvested from patients in England, Scotland, and Wales, the scientists estimated that more than 491,000 fewer people than expected started taking blood pressure-lowering medication when the pandemic was at its peak between March 2020 and the end of July 2021. .” That seems like good news on the face of it.

52

52